

Title (en)
COMPOUNDS AND METHODS

Title (de)
VERBINDUNGEN UND VERFAHREN

Title (fr)
COMPOSES ET PROCEDES

Publication
EP 1146790 A4 20040317 (EN)

Application
EP 00909984 A 20000125

Priority
• US 0001908 W 20000125
• US 11704499 P 19990125

Abstract (en)
[origin: WO0042852A1] This invention relates to substituted heterocyclic compounds which are modulators, agonists or antagonists, of the CCR5 receptor. In addition, this invention relates to the treatment and prevention of disease states mediated by CCR5, including, but not limited to, asthma and atopic disorders (for example, atopic dermatitis and allergies), rheumatoid arthritis, sarcoidosis and other fibrotic diseases, atherosclerosis, psoriasis, autoimmune diseases such as multiple sclerosis, and inflammatory bowel disease, all in mammals, by the use of substituted heterocyclic compounds which are CCR5 receptor antagonists. Furthermore, since CD8+ T cells have been implicated in COPD, CCR5 may play a role in their recruitment and therefore antagonists to CCR5 could provide potential therapeutic in the treatment of COPD. Also, since CCR5 is a co-receptor for the entry of HIV into cells, selective receptor modulators may be useful in the treatment of HIV infection.

IPC 1-7
A01N 43/58; A61K 31/4418; A61K 31/495; A61K 31/496

IPC 8 full level
C07D 295/20 (2006.01); **A61K 31/438** (2006.01); **A61K 31/4418** (2006.01); **A61K 31/495** (2006.01); **A61K 31/496** (2006.01); **A61P 1/00** (2006.01); **A61P 9/10** (2006.01); **A61P 11/00** (2006.01); **A61P 11/06** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **A61P 21/00** (2006.01); **A61P 25/00** (2006.01); **A61P 29/00** (2006.01); **A61P 31/18** (2006.01); **A61P 37/00** (2006.01); **A61P 43/00** (2006.01); **C07D 211/70** (2006.01); **C07D 491/107** (2006.01)

CPC (source: EP)
A61K 31/4418 (2013.01); **A61K 31/495** (2013.01); **A61K 31/496** (2013.01); **A61P 1/00** (2017.12); **A61P 9/10** (2017.12); **A61P 11/00** (2017.12); **A61P 11/06** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 19/02** (2017.12); **A61P 21/00** (2017.12); **A61P 25/00** (2017.12); **A61P 29/00** (2017.12); **A61P 31/18** (2017.12); **A61P 37/00** (2017.12); **A61P 43/00** (2017.12)

Citation (search report)
• No further relevant documents disclosed
• See references of WO 0042852A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0042852 A1 20000727; AU 3215500 A 20000807; EP 1146790 A1 20011024; EP 1146790 A4 20040317; JP 2002535256 A 20021022

DOCDB simple family (application)
US 0001908 W 20000125; AU 3215500 A 20000125; EP 00909984 A 20000125; JP 2000594326 A 20000125